MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.


Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
On location

Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS

More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...

Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS

Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS

Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients...

Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS

A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results...
On location

Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia Vera

PTG-300, a hepcidin mimetic, eliminated the need for phlebotomy and the resultant iron deficiency in patients with high- and low-risk polycythemia vera (PV), according...

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Jacqueline Garcia, MD, discusses results from a phase Ib study evaluating venetoclax and azacitidine in patients with treatment-naïve high-risk myelodysplastic syndromes.

Optimizing Outcomes With Azacitidine Treatment in Patients With MDS

Delays in treatment with azacitidine predicted lower survival rates in patients with myelodysplastic syndromes (MDS), independently of the International Prognostic Scoring System (IPSS) score...

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Block title